Egetis Therapeutics AB (publ)
EGTX.ST · Health Technology · Biotechnology · SE
25 employees · egetis.com
About
Egetis Therapeutics AB (publ) is a biotechnology company based in Stockholm, Sweden, operating within the healthcare sector. The company has a workforce of 25 full-time employees and went public via an IPO on April 7, 2011. Its website is https://www.egetis.com/. Egetis focuses on developing new pharmaceutical treatments for serious diseases, with a pipeline including Emcitate, PledOx, and Aladote. Emcitate is designed for the treatment of MCT8 deficiency, PledOx aims to reduce nerve damage caused by chemotherapy, and Aladote targets the reduction of acute liver injury risk associated with acetaminophen or paracetamol poisoning. The company is listed on the Stockholm Stock Exchange under the ticker EGTX.ST and holds the ISIN SE0003815604. Egetis Therapeutics AB (publ) operates as a public company with a focus on innovative drug development for unmet medical needs. Its current operations and product development stages are not detailed in the provided information.
Annual results
Reported figures, SEK · revenue up 34.8% in 2025
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | 62.0M | -342M | -551.6% | — |
| 2024 | 46.0M | -343M | -745.7% | — |
| 2023 | 57.0M | -326M | -571.9% | — |
| 2022 | 22.0M | -189M | -859.1% | — |
| 2021 | 38.0M | -104M | -273.7% | — |
EGTX.ST in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Egetis Therapeutics AB (publ) are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.